Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

被引：0
|
作者：
Hu, Qiongjie [1 ,3 ]
Shi, Yueli [1 ,2 ]
Wang, Huang [4 ]
Bing, Liuwen [3 ]
Xu, Zhiyong [1 ,2 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Dept Resp & Crit Care Med, Yiwu 322000, Zhejiang, Peoples R China
[2] Zhejiang Key Lab Precis Diag & Treatment Lung Canc, Yiwu 322000, Peoples R China
[3] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Hangzhou 310013, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Nanjing, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2025年 / 14卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Cancer immunotherapy; Immune checkpoint blockade; Post-translational modifications; Ubiquitination; Phosphorylation; ANTIBODY-BASED PROTACS; CELL LUNG-CANCER; SIRP-ALPHA; TUMOR MICROENVIRONMENT; PD-L1; EXPRESSION; BREAST-CANCER; T-CELLS; COINHIBITORY PATHWAYS; REGULATES ANTITUMOR; ACQUIRED-RESISTANCE;
D O I：
10.1186/s40164-025-00627-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy targeting immune checkpoints has gained traction across various cancer types in clinical settings due to its notable advantages. Despite this, the overall response rates among patients remain modest, alongside issues of drug resistance and adverse effects. Hence, there is a pressing need to enhance immune checkpoint blockade (ICB) therapies. Post-translational modifications (PTMs) are crucial for protein functionality. Recent research emphasizes their pivotal role in immune checkpoint regulation, directly impacting the expression and function of these key proteins. This review delves into the influence of significant PTMs-ubiquitination, phosphorylation, and glycosylation-on immune checkpoint signaling. By targeting these modifications, novel immunotherapeutic strategies have emerged, paving the way for advancements in optimizing immune checkpoint blockade therapies in the future.
引用
收藏
页数：28
相关论文
共 50 条
  • [31] Post-translational modifications of EZH2 in cancer
    Zhongwei Li
    Minle Li
    Diandian Wang
    Pingfu Hou
    Xintian Chen
    Sufang Chu
    Dafei Chai
    Junnian Zheng
    Jin Bai
    Cell & Bioscience, 10
  • [32] Protein post-translational modifications in the regulation of cancer hallmarks
    Haiying Wang
    Liqian Yang
    Minghui Liu
    Jianyuan Luo
    Cancer Gene Therapy, 2023, 30 : 529 - 547
  • [33] Targeting post-translational modifications of histones for cancer therapy
    Hsu, Y-C.
    Hsieh, Y-H.
    Liao, C-C.
    Chong, L-W.
    Lee, C-Y.
    Yu, Y-L.
    Chou, R-H.
    CELLULAR AND MOLECULAR BIOLOGY, 2015, 61 (06) : 69 - 84
  • [34] Regulation of ovarian cancer by protein post-translational modifications
    Zhu, Qiugang
    Zhou, Huimin
    Xie, Feiting
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] Regulation of HNRNP family by post-translational modifications in cancer
    Li, Bohao
    Wen, Mingxin
    Gao, Fei
    Wang, Yunshan
    Wei, Guangwei
    Duan, Yangmiao
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [36] Editorial: The role of post-translational modifications in cancer biology
    Srivastava, Swati
    Tripathi, Anurag
    Trivedi, Arun Kumar
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Post-Translational Modifications That Drive Prostate Cancer Progression
    Samarzija, Ivana
    BIOMOLECULES, 2021, 11 (02) : 1 - 44
  • [38] Protein Post-translational Modifications in Head and Neck Cancer
    Zhang, Hongbo
    Han, Wei
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [39] Post-translational modifications on mitochondrial metabolic enzymes in cancer
    Peng, Yunhua
    Liu, Huadong
    Liu, Jiankang
    Long, Jiangang
    FREE RADICAL BIOLOGY AND MEDICINE, 2022, 179 : 11 - 23
  • [40] Post-translational modifications of EZH2 in cancer
    Li, Zhongwei
    Li, Minle
    Wang, Diandian
    Hou, Pingfu
    Chen, Xintian
    Chu, Sufang
    Chai, Dafei
    Zheng, Junnian
    Bai, Jin
    CELL AND BIOSCIENCE, 2020, 10 (01):
12345